Clinical Trials Logo
  1. Home
  2. Cushing's Disease
  3. NCT03346954

Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's Disease — IMPEC  

Cushing's Disease Clinical Trial

Official title:
Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's Disease

Clinical Trial Summary

Cushing's disease is characterized by the existence of a benign pituitary tumor developed from corticotropic cells responsible for excessive ACTH secretion. This results in hypercorticism causing high morbidity and mortality and severely impairing quality of life. The etiological diagnosis is based on Magnetic Resonance Imaging (MRI). However, pituitary MRI revealed a pituitary tumor in only 60% of patients. The diagnostic procedure is complicated by the existence of extra pituitary tumors responsible for ACTH ectopic secretion. This rare etiology imposes, in the absence of typical pituitary image, the realization of catheterization of the lower petrosal sinuses. Treatment of Cushing's disease is based on transsphenoidal surgical management, even in the absence of a formal MRI image, if pituitary origin is confirmed by the catheterization. Although pituitary surgery without identified target is part of French recommendations, this surgery is associated with a high risk of failure and morbidity. Optimization of the management of patients' with Cushing's disease thus requires the improvement of the diagnostic methods. Hypothesis of our study is that [11C] MET MRI-PET may be performed as a first-line MRI for suspected Cushing's disease and may limit indications for catheterization of lower petrosal sinuses. Its localizing value should also make it possible to improve the surgical results with a better identification of the adenoma

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03346954
Study type Interventional
Source Hospices Civils de Lyon
Contact
Status Completed
Phase N/A
Start date December 11, 2017
Completion date August 31, 2020
View Details
See also
  Status Clinical Trial Phase
Terminated NCT00881283 - Long-term Cardiovascular Risk in Cured Cushing's Patients
Completed NCT02568982 - Cushing's Disease Complications
Completed NCT02697734 - Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease Phase 3
Completed NCT01374906 - Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease Phase 3
Recruiting NCT03364803 - Collecting Information About Treatment Results for Patients With Cushing's Syndrome
Not yet recruiting NCT02603653 - Assessment of Persistent Cognitive Impairment After Cure of Cushing's Disease N/A
Completed NCT01371565 - Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome Phase 3
Recruiting NCT00845351 - Preoperative Bexarotene Treatment for Cushing's Disease Phase 1/Phase 2
Completed NCT00889525 - Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Phase 3
Completed NCT02060383 - Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Phase 4
Recruiting NCT03474601 - Seoul National University Pituitary Disease Cohort Study
Recruiting NCT04339751 - Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease Phase 2
Not yet recruiting NCT04569591 - Corticotrophin-releasing Hormone (CRH) Stimulation for 18F-FDG-PET Detection of Pituitary Adenoma in Cushing s Disease N/A
Recruiting NCT02484755 - Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease Phase 2
Completed NCT01794793 - Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies Phase 4
Completed NCT00434148 - Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease Phase 3
Withdrawn NCT01925092 - Mifepristone in Children With Refractory Cushing's Disease Phase 3
Completed NCT01582061 - An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. Phase 3
Recruiting NCT03708900 - Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Disease Phase 2
Terminated NCT00612066 - Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease) Phase 2